Skip Navigation


Annals of Oncology Advance Access originally published online on December 15, 2007
Annals of Oncology 2008 19(1):191-192; doi:10.1093/annonc/mdm542
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/1/191-a    most recent
mdm542v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Witzel, I. D.
Right arrow Articles by deWit, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Witzel, I. D.
Right arrow Articles by deWit, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Trastuzumab in pregnancy associated with poor fetal outcome

The first 10% of the full text of this article appears below.

Trastuzumab (Herceptin®), an mAb targeting the epidermal growth factor receptor HER2, is used as standard of care in patients with HER2-overexpressing tumors. A relevant number of younger women with childbearing potential are being treated with this immunoglobulin (IgG1) antibody. We report a patient with metastatic breast cancer who was treated with trastuzumab during pregnancy. The baby was born preterm and developed a severe respiratory distress and capillary leak syndrome with fatal outcome.

The patient was diagnosed at the age of 29 with a 3-cm left breast . . . [Full Text of this Article]

I. D. Witzel1,*, V. Müller1, E. Harps2, F. Janicke1 and M. deWit3

1 Department of Gynecology
2 Department of Pediatrics, University Hospital, Hamburg
3 Department of Haematology and Oncology, University Hospital, Hamburg and Department of Haematology and Oncology, Vivantes Klinikum Neukoelln, Germany

* E-mail: iwitzel@uke.uni-hamburg.de)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?